SCHEMBL7345656

SCHEMBL7345656

CCOC(=O)CNS(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.62
MEP1B Q16820 1/20 0.60
PKM P14618 3/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 1/20 0.56
NPC1 O15118 1/20 0.56
GAA P10253 1/20 0.56
RAB9A P51151 1/20 0.56
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54
HTT P42858 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7383813 0.88 ALDH1A1 (0.71) ALDH1A1MEP1BPKMSMN1; SMN2HPGD
SCHEMBL257480 0.86 ALDH1A1 (0.67) ALDH1A1PKMSMN1; SMN2HPGDKDM4E
SCHEMBL28746053 0.86 ALDH1A1 (0.57) ALDH1A1MEP1BPKMSMN1; SMN2HPGD
SCHEMBL7261912 0.84 ALDH1A1 (0.64) ALDH1A1PKMSMN1; SMN2HPGDKDM4E
SCHEMBL6506619 0.84 ALDH1A1 (0.64) ALDH1A1MEP1BPKMSMN1; SMN2HPGD
SCHEMBL13917758 0.82 ALDH1A1 (0.62) ALDH1A1MEP1BPKMSMN1; SMN2HPGD
SCHEMBL28849841 0.82 ALDH1A1 (0.62) ALDH1A1MEP1BPKMSMN1; SMN2HPGD
SCHEMBL8434115 0.82 MEP1B (0.60) ALDH1A1MEP1BPKMSMN1; SMN2HPGD
SCHEMBL15595362 0.82 HTT (0.56) ALDH1A1MEP1BSMN1; SMN2LMNAHTT
SCHEMBL4173740 0.81 MEP1B (0.67) ALDH1A1MEP1BPKMSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020150446-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-07-23 WO disclosed
EP-0845987-A4 C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN FIBROGEN INC (US) 2000-05-24 EP disclosed
EP-0845987-A1 C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN FIBROGEN, INC. (US) 1998-06-10 EP disclosed
EP-0606046-B1 Arylsulfonamido-substituted hydroxamic acids CIBA GEIGY AG (CH) 1997-10-08 EP disclosed
US-5672615-A MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS NOVARTIS CORPORATION (US) 1997-09-30 US disclosed
US-5646167-A ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
WO-1997005865-A1 C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN FIBROGEN, INC. (US) 1997-02-20 WO disclosed
US-5552419-A METALLOPROTEINASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-09-03 US disclosed
US-5506242-A METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
US-5455258-A Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0606046-A1 Arylsulfonamido-substituted hydroxamic acids CIBA-GEIGY AG (CH) 1994-07-13 EP disclosed